Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026
Ground breaking medical innovation, better patient outcomes, strong financial returns.
Brandon has been effective in raising successive funds that collectively cover the spectrum of life science venture investing. We also have a co-investment arrangement with our investors, providing significant capacity to support our advancing portfolio companies.
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom
Investment
Portfolio
Recognising the effort required to commercialise a great idea, we partner with entrepreneurs for the long-haul, working collaboratively with them to support the development and commercialisation of their technology, thereby creating value for their teams, our investors and ultimately benefiting patients.
We like to invest early - we have been the founding investor for most of our current portfolio companies
